Established in 2005 by Dr. Raphael Mayer, Smart Assays is an Israeli CRO (Contract Research Organization), situated at the Weizmann Science Park.

Smart Assays has specific expertise and a formidable track record in the following areas:

- Assay development
- Research histopathology
- Bioanalytic
- Scientific Due diligence - hands on
- Maturation of early stage projects
- Untangling of elaborate biochemical queries, such as “mechanism of action”
Our Facilities

**Smart Assays** operates in a 350m² state-of-the-art facility, at the Weizmann Science Park, equipped with all necessary instruments and integrated QA system.

**Special equipment:**
- Plate reader: ClarioStar – BMG (First In Israel)
- Patch Clamp Port-a Patch - Nanion(First In Israel)
- MSMS Triple Quadrupole LC/MS/MS System - TSQ Quantum Access Max H-ESI II probe (Thermo Fisher)
- uHPLC Ultimate 3000 Quaternary (Dionex)
- HPLC Jasco
- Fully set for histology, animal and microbial tissue culture and more...
Quality Assurance

Smart Assays QA Statement
Veatriki Fraggi Rankis, Head of QA and Project Manager

**QA statement:**
We state that we are operating under internal regulatory procedures which include amongst others:

1. Commitment to the continuous improvement of our QA system.
2. Detailed experimental design and documentation, writing of policies and SOPs for assays, devices, safety and management issues. Assays that are intended for validation or use in clinical studies are being qualified and formal qualification report is being written. As needed, test results are reported in an official test report form.
3. Handling of specification failures and non-conformities and conducting investigations as needed.
4. Periodic calibration and maintenance of equipment, devices and pipettes.
5. Our refrigerators and freezers are connected to temperature control system which alerts for any temperature changing.
6. Personnel training on safety and QA issues.
7. Only in the last year we went through couple of audits.

**Certification**
- ISO 9001 for first granted at February 2017
Raphael Mayer, Ph.D.
Founder & CEO
Dr. Mayer is a graduate of Hebrew University & Rockefeller University, NY.
Before founding **Smart Assays** Dr. Mayer was head of Assay Development Dep. At Quark Biotechnology Inc. Author and co-author of 20 scientific publications.

Merav Marom Shamur, Ph.D.
Director of Operation & Project Manager
Dr. Shamur is highly qualified biochemist and electrophysiologist with 15 years of academic and industrial professional experience. Author and co-author of six scientific publications.

Veatriki Fraggi Rankis, M.Sc.
Head of QA & Project Manager
Mrs F. Rankis is a graduate of Hebrew University.
Before joining Smart Assays at 2011 she was a researcher at Quark Biotechnology Inc. for 9 years.

Ronny Peri-Naor, Ph.D
Head of Bio-Analytical Unit and Project Manager
Dr Peri-Naor is highly qualified biochemist and bio-analytical researcher with 12 years of academic and industrial professional experience. Author and co-author of six scientific publications.
Our Areas of Expertise

Homepage of our website: https://www.assays.co.il/
Scientific Due-Diligence

Before investment we offer focused reproduction of major findings and proof of concept aimed at project validation. Decrease the investor risks timely and at a fraction of the price.
Early Stage Projects’ Maturation

We conduct focused R&D aimed at producing clear proof-of-concept data that is our clients’ propriety.

We develop the Early Stage company’s core assets, and prepare it for the next step: a significant external investment.
Choosing to conduct your research with Smart Assays FTE program assures you:

❖ A PhD researcher
❖ 100% committed to conducting your R&D
❖ Provided with constant scientific support and management
❖ Works within a state-of-the-art equipped laboratory in high level QA standards
❖ Full documentation for reproducibility
❖ At the end of the project, if so agreed, your FTE researcher can transfer to your facilities for implementation or for further work on the project.
Marketing and Business Development Overseas

The Aptuit agreement

- Signature March 6\textsuperscript{th} 2017
- Event at the British Embassy June 14\textsuperscript{th} 2017
- Collaboration on Mouse bleomycin Histopathology first Invoice December 2017

The agreement is not implemented since Evotec took over Aptuit
Smart Assays Signs Cooperation Deal With Aptuit

From Globes by Gali Weinrab


�缋缌_conn ACCOUNT MEMBERSHIP

มาข่าร ดร. กาลี วีนรับ

American company Aptuit has signed a cooperation agreement with Smart Assays, a global leading company in the field of advanced biotechnology, for the development of in vitro methods.

Aptuit, a subsidiary of HealthCare Royalty Group Inc., was established in 2007 and specializes in the development of advanced biological methods and products.

The cooperation agreement will enable the parties to develop new in vitro methods for the evaluation of biological agents, including a wide range of therapeutic agents. This will provide a significant advantage to both companies and their clients.

Aptuit already provides in vitro testing services for a variety of therapeutic agents, and Smart Assays specializes in the development of advanced biological methods and products.

This cooperation agreement is a significant step for both companies and their clients, as it will enable the development of new in vitro methods for the evaluation of biological agents, including a wide range of therapeutic agents.

The agreement will enable the parties to develop new in vitro methods for the evaluation of biological agents, including a wide range of therapeutic agents. This will provide a significant advantage to both companies and their clients.

The agreement also includes the exchange of information and the sharing of resources, which will enable the parties to develop new in vitro methods for the evaluation of biological agents, including a wide range of therapeutic agents.

The agreement also includes the exchange of information and the sharing of resources, which will enable the parties to develop new in vitro methods for the evaluation of biological agents, including a wide range of therapeutic agents.

The agreement also includes the exchange of information and the sharing of resources, which will enable the parties to develop new in vitro methods for the evaluation of biological agents, including a wide range of therapeutic agents.

The agreement also includes the exchange of information and the sharing of resources, which will enable the parties to develop new in vitro methods for the evaluation of biological agents, including a wide range of therapeutic agents.
From Globes by Gali Weinrab
Co-Publication of Our Scientific Work With Our Customer From Canada (2017)
We are leaders of Open-screen - Israel
https://www.eu-openscreen.eu/

EU project OLEUM: Assuring the quality and authenticity of olive oil
https://www.eufic.org/en
The Team

- 11 Employees
- 8 with PhD
- 2 with MSc

Managers are 7-8 years at Smart Assays
Some of Our Successes

For: TEVA (TEVA) NASDAQ
Undisclosed
SMART ASSAYS

For: WEIZMANN INSTITUTE OF SCIENCE
Feasibility Study
SMART ASSAYS

For: meddiwound LTD (MDWD) NASDAQ
Method Development for Batch Release and a Mode of Action Research Approved by EMA
SMART ASSAYS

For: Carmentix Singapore
Pre-clinical R&D
SMART ASSAYS

For: MERCK Germany
Antibody characterization
SMART ASSAYS

For: eCAM Biotherapeutics
Owned subsidiary of MSD
Antibody characterization
SMART ASSAYS

For: CANFITE BioPharma Ltd (CANF) NASDAQ
Development of an A3AR Biomarker Test Kit to Predict Patients' Response to Company's Drugs
SMART ASSAYS

For: replicor North America
Kinetics analysis
SMART ASSAYS
Thank You

Raphael Mayer (PhD)

mayer@assays.co.il

Tel. +(972)- 54-724 1251

Skype: Raphael.Mayer3

PO Box 4182

Weizmann Science Park 74140

www.assays.co.il